medigraphic.com
ISSN 0028-3851 (Impreso)

2005, Número 4

<< Anterior Siguiente >>

Rev Neurol Neurocir Psiquiat 2005; 38 (4)


Importancia dada por el psiquiatra a la adherencia al tratamiento en pacientes psiquiátricos

Garcia R, Mazza R, Martins NE, Ramos AM, de Oliveira SM, Santos AF, Garcia LM

Idioma: Portugués
Referencias bibliográficas: 18
Paginas: 129-134
Archivo PDF: 65.76 Kb.


FRAGMENTO

Sin resúmen


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Blackwell B. Treatment adherence. Br J Psychiatry 1976; 129:513-31.

  2. Garcia R. Papel da Motivação na Adesão ao Tratamento Psiquiátrico. Rev Bras Neurol Psiq, 2001; 5(3); 97-101).

  3. Butter C, Rollnick S, Stott N. The practitioner, the patient and resistance to change: recent ideas on compliance. Can Med Assoc J 1996; 154: 1357-67.

  4. Garcia R, Schooley RT, Badaró R. An adherence trilogy is essential for long-term HAART success. Brazil J Infect Diseas 2003; 7(5): 307-14.

  5. Weiden PJ, Mott T, Curcio N. Recognition and management of neuroleptic noncompliance. In Contemporary issues in the treatment of schizophrenia. Washington, DC: Shirqui C, Nasrallah H. (eds.) American Psychiatry Association Press, 1995; 411-34.

  6. Gerhardt U. Ideas about illness. New York: New York University Press; 1989; In: Adesão a tratamentos médicos. Santos JQ Psiq Prat Med 2000; 33(1): 14-6.

  7. Santos JQ. Adesão a tratamentos médicos. Psiq Prat Méd. 2000; 33(1): 14-6.

  8. Leppik IE. How to get patients with epilepsy to take their medication: The problem of noncompliance. Postgrad Med 1990; 88: 253-6.

  9. Rittmannsberger H, Packinger T, Keppelmuller P, Wancata J. Medication adherence among psychotic patients. Psychiatr Service February 2004; 55: 174-9.

  10. Green LW, Simons-Morton DG. Denial, delay and disappointment: Discovering and overcoming the causes of drug errors and missed appointments (chap 1). In: Schmidt D, Leppik IE, (eds.) Compliance in epilepsy. New York, NY. Elsevier Science Publishers. BV (Biomedical Division); 1988: 7-21.

  11. Misdrahi D, Llorca PM, Lancon C, Bayle FJ. Compliance in schizophrenia: predictive factors, therapeutical considerations and research implications. Encephale 2002; May-Jun; 28:266-72.

  12. Medication Regimens: causes of non compiance. Washington, D.C.; Office of the Inspector General, Department of Health and Human Services. 1990; June: 12-14.

  13. Roose SP “Compliance: the impact of adverse events and tolerability on the physician’s treatment decisions”. Eur Neuropsychopharmacol. 2003; 13 Sppl: 585-592.

  14. Van Putten T, May PRA. Subjective response as a predictor of outcome in pharmacotherapy. Arch Gen Psychiatry 1978; 35: 477-480.

  15. Van Putten T, May PRA, Marder SR, et al. Subjective response to antipsychotic drugs. Arch Gen Psychiatry 1981; 38: 187-190.

  16. Hogan TP, Awad AG. Pharmacotherapy and suicide risk in schizophrenia . Can J Psychiatry 1983; 28: 277-281.

  17. Naber D, Walther A, Kirchere T, et al. In Prediction of neuroleptic treatment outcome in schizophrenia: concepts and methods. Edited by Gaebel W, Awad AG. Heidelberg: Springer-Verlag 1994; pp. 111-22.

  18. Gabbard GO, Kay J. The fate of integrated treatment: what ever happened to the biopsychosocial psychiatrist? Am J Psychiatry 2001; 158: 1956-63.




2020     |     www.medigraphic.com